NECTIN4 and neoplasm: A novel Nectin-4-targeting antibody‒drug conjugate (ADC) (ASG-22ME) was developed by Challita-Eid et al. This ADC comprises a fully human-targeting Nectin-4 antibody and the potent microtubule-disrupting agent monomethyl auristatin E segment.242 Campbell et al. performed a preclinical evaluation to determine the biodistribution and tumour binding capacity of [89Zr]Zr-DFO-AGS-22M6 and [18F]AGS-22M6.243 The results revealed an average high uptake of [89Zr]Zr-DFO-AGS-22M6 (45.3 ± 2.4%ID/g) in MDA-MB-231-Nectin-4 tumours in mice.